The contemporary spectrum of multiple sclerosis misdiagnosisAndrew Solomon, Brian G. Weinshenker, Dennis Bourdette et al.|Neurology|2016Cited by 324
Five years of ocrelizumab in relapsing multiple sclerosisStephen L. Hauser, Xavier Montalbán, Ludwig Kappos et al.|Neurology|2020Cited by 159
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S. Wolinsky, Stephen L. Hauser, Douglas L. Arnold et al.|The Lancet Neurology|2020Cited by 150
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)Ellen M. Mowry, Richard A. Rudick, Robert Bermel et al.|Frontiers in Neurology|2020Cited by 91
Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteriaAndrew Solomon, Brian G. Weinshenker, Roman Pettigrew et al.|Multiple Sclerosis Journal|2020Cited by 68